Compositions and methods for generating a persisting population of T cells useful for the treatment of cancer

Patent metadata

Field	Value
Publication number	US-10040846-B2
Application number	US-201314375015-A
Country	US
Kind code	B2
Filing date	Feb 22, 2013
Priority date	Feb 22, 2012
Publication date	Aug 7, 2018
Grant date	Aug 7, 2018

Abstract

The present invention provides compositions and methods for generating a genetically modified T cells comprising a chimeric antigen receptor (CAR) having an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain, wherein the T cell exhibits prolonged exponential expansion in culture that is ligand independent and independent of the addition of exogenous cytokines or feeder cells.

First claim

What is claimed is:

1. An isolated nucleic acid sequence encoding a chimeric antigen receptor (CAR), wherein the CAR comprises an anti-c-Met antibody or fragment thereof, an IgG4 hinge domain, a CD28 transmembrane domain, a CD28 costimulatory signaling region, and a CD3 zeta signaling domain, and further wherein the CAR comprises the amino acid sequence of SEQ ID NO: 1.

2. A T cell comprising a nucleic acid sequence that expresses a chimeric antigen receptor (CAR), the CAR comprising an anti-c-Met antibody or fragment thereof, an IgG4 hinge domain, a CD28 transmembrane domain, a CD28 costimulatory signaling region, and a CD3 zeta signaling domain, and further wherein the CAR comprises the amino acid sequence of SEQ ID NO: 1.

3. A vector comprising a nucleic acid sequence encoding a chimeric antigen receptor (CAR), the CAR comprising an anti-c-Met antibody or fragment thereof, an IgG4 hinge domain, a CD28 transmembrane domain, a CD28 costimulatory signaling region, and a CD3 zeta signaling domain, and further wherein the CAR comprises the amino acid sequence of SEQ ID NO: 1.

Assignees

• Univ Pennsylvania

Inventors

• Frigault Matthew J
• Zhao Yangbing
• Scholler John
• June Carl H

Classifications

• C07K14/70521

  CD28, CD152 · CPC title

• C12N2510/00

  Genetically modified cells · CPC title

• C07K2319/33

  fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies · CPC title

• C07K14/7051

  T-cell receptor (TcR)-CD3 complex · CPC title

• C12N5/0636 Primary

  T lymphocytes · CPC title